

What is the Medical Monitoring Project (MMP)?

- MMP is an ongoing population-based surveillance system to assess clinical outcomes and behaviors of HIV-infected adults receiving care in the United States.
- It is currently conducted in 17 states and 6 cities by local and state public health departments in collaboration with the Centers for Disease Control and Prevention (CDC).
- Texas MMP and Houston MMP are separately funded. The data below excludes Houston MMP.

Who Participated in Texas MMP 2011?

Facilities - participated/sampled - 29/34 (85%)

Public -14/14(100%)
Private -14/19 (74%), 5 refusals
Federal -1/1 (100%)

Patients - participated/sampled - 260/395 (66%)

Public - 187/269 (70%), 26 refusals, 56 other*
Private - 73/110 (66%), 22 refusals, 15 other*
Federal - 0/16 (0%), IRB delays

*LTFU, no response/no show, moved, jailed, deceased

Cities - Austin, Bryan, Conroe, Corpus Christi, Dallas, Edinburg, El Paso, Ft. Worth, Galveston, Laredo, Longview, Lubbock, Odessa, Plano, San Antonio, Temple, Waco

•Data presented based on 2011 patient self-reported interviews (N=260)

Patient Demographic Information


Race/Ethnicity and Age at the Time of Interview by Sex

	Male n=208	Female n=46	Trans- gender n=4	Total n=258‡
White, non-Hispanic	74 (36%)	11(24%)	**	85 (33%)
Black, non-Hispanic	44 (21%)	20 (43%)	**	65 (25%)
Hispanic	81 (39%)	15 (33%)	**	97 (38%)
Multiracial	9 (4%)	**	**	11 (4%)
	Male n=210	Female n=46	Transgen- der n=4	Total n=260
18-24	6 (3%)	**	**	7 (3%)
25-34	24 (11%)	11 (24%)	**	35 (13%)
35-44	58 (28%)	15 (33%)	**	74 (28%)
45-54	91 (43%)	12 (26%)	3 (75%)	106 (41%)
55+	31 (15%)	7 (15%)	**	38 (15%)

‡ Participants who reported 'don't know' to race are excluded

****NOTE:** To protect MMP participant confidentiality the CDC restricts the reporting of variables where n<3. Variables affected include transgender, Asian, Native Hawaiian/Pacific Islander, American Indian and Alaska Native.

Medical Coverage in the Past 12 Months*



* Categories are not mutually exclusive

† Other types of public assistance programs

In the past 12 months:

- 25% had no health insurance
- 8% had an HIV related ER visit
- 7% had an HIV related hospitalization

Time between HIV Diagnosis and Entry into HIV Care Among Participants Diagnosed in the Past 5 years

	Male n=53	Female n=12	Total n=65
≤ 3 months	46 (87%)	11 (92%)	57 (88%)
4 - 11 months	7 (13%)	**	8 (12%)

Main Reasons for Delaying Entry into HIV Care

- Didn't want to talk about being HIV positive or unable to get earlier appointment

Self Reported Routine HIV Lab Tests

Median Number in the Past 12 Months	Male*		Female*		Trans-gender*	
CD4 counts	4 (n=205)		3 (n=39)		2 (n=3)	
HIV Viral Load	4 (n=203)		3 (n=41)		1 (n=3)	
Most Recent CD4 Count	Male† (n=206)		Female† (n=41)		Total** (n=247)	
	#	%	#	%	#	%
0-49	**		0		**	
50-99	3	1	**		5	2
100-199	8	4	**		9	4
200-349	32	16	7	17	39	15
350-499	35	17	5	12	41	16
500+	86	42	15	37	103	42
Don't Know	40	19	11	27	51	21
Most Recent Viral Load	Male‡‡ (n=205)		Female‡‡ (n=42)		Total** (n=247)	
	#	%	#	%	#	%
Undetectable	141	69	21	50	165	67
<5,000	19	9	5	12	24	10
5,000 to 100,000	11	5	3	7	14	5
>100,000	4	2	0		4	1
Don't Know	30	15	13	31	43	17

* Among males/females/transgender who had a CD4 count or viral load test in the past 12 months

† Among males/females who reported a most recent CD4 count

‡‡Among males/females who reported a most recent viral load

Antiretroviral Therapy in the Past 12 Months, N=260

- Currently taking antiretroviral (ARV) meds: 96% (n=249)
- Currently not on ARV: 2% (n=5)
- Treatment Naïve: 3% (n=7)
 - Main reason: Doctor advised to delay treatment (71%, n=5)

Sexual Behavior

Number of Sexual Partners in the Past 12 Months

n=173	MSW** n=32	MSM** n=112	MSMW** n=3	WSM** n=26
One	24 (75%)	48 (43%)	0	23 (88%)
Two or more	8 (25%)	64 (57%)	3 (100%)	3 (12%)
No. of Partners	1-2	1-62	2-10	1-2

**Men who have sex w/ women (MSW), Men who have sex w/ men (MSM), Men who have sex w/ men & women (MSMW), Women who have sex w/ men (WSM)

- 33% (n=84) had no sexual partners in the past 12 months

Reported Unprotected Vaginal or Anal Sex with at least 1 Partner in the Past 12 Months

n=154	MSW n=32	MSM n=98	WSM n=24
Yes	5 (16%)	50 (51%)	7 (29%)
No	27 (84%)	48 (49%)	17 (71%)

Unmet Need for Ancillary Services in the Past 12 Months

Top 3 Unmet Service Types, N=260	Services Received		Services Needed but Didn't Receive
	Yes	No	
Dental Services	142 (55%)	118 (45%)	68/118 (58%)
Transportation Services	45 (17%)	215 (83%)	27/215 (13%)
HIV Peer Group Support	29 (11%)	231 (89%)	33/231 (14%)


Main reason didn't receive needed services:

Dental services - too expensive or lack insurance
 Transportation services - didn't know where to go, who to call
 HIV peer group support - didn't know where to go, who to call

Self-Reported Substance Use in the Past 12 Months

- 2% (n=6) injected drugs in the past 12 months
- 73% (n=187) used alcohol in past 12 months
 - Of these, 55% (n=142) used alcohol in past 30 days
 - Of these, 33% (n=47) had at least 4 or more drinks on a typical day when drinking

Top 6 Commonly Used Non-Injection Drugs In the Past 12 Months (Excluding Alcohol)



Why should I participate in MMP?

- MMP's true success depends upon the participation of HIV care providers like you, and your patients.
- MMP presents a unique opportunity to contribute to knowledge about HIV care in the U.S.
- Texas MMP presentations:
 1. Sexual risk behaviors among persons in medical care for HIV in Texas, 2011 National HIV Prevention Conference
 2. Adherence to HIV clinical treatment guidelines among healthcare providers in Texas, 2012 International AIDS Conference
 3. Texas 2009 MMP: Antiretroviral data reliability and source agreement, 2012 International AIDS Conference

Texas MMP Website:
http://www.dshs.state.tx.us/hivstd/eps_mmp/MMP.shtm

CDC MMP Website:
<http://www.cdc.gov/hiv/topics/treatment/mmp/index.htm>

Prepared by: Chelsea McGill, MPH, Sabeena Chintapalli, MPH, & Sylvia Odem, MPH
 Issue Date: 08/08/12

2011 Texas MMP Team

Jerry Burrola	Elias Cantu	Sabeena Chintapalli
Jim Phillips	Esther Reyna	Stephen Brown
Chelsea McGill	Mark Heinzke	Nicole Hawkins
Douglas Schuster	Douglas Shehan	Sylvia Odem

Sharon K Melville, MD, MPH, Principal Investigator
 Praveen R Pannala, MD, MPH, Co Principal Investigator

Questions about MMP?

- If you are interested in learning more about MMP or have any questions, please contact:

Sylvia L Odem, MPH, Project Coordinator
Sylvia.Odem@dshs.state.tx.us (512) 533-3053

Philip Keiser, MD
 Lead Provider Advisory Board Member
pkeise@gmail.com

Judith Dillard
 Lead Community Advisory Board Member
msjdillard@netzero.net